Eli Lilly’s diabetes and obesity therapy tirzepatide could find a use as a treatment for obstructive sleep apnoea (OSA) after hitting the mark in a pair of phase 3 trials. OSA is a prevalent ...

Eli Lilly's dual GLP-1/GIP agonist tirzepatide has been shown to reduce the risk of worsening disease in people with heart failure and obesity in a phase 3 trial, the first to show a benefit on ...

AMRA Medical, as part of a collaborative effort composed of researchers from the University of Glasgow, University Hospitals Cleveland, and Eli Lilly and Company, recently conducted a detailed ...

If you’re concerned about the current status of tirzepatide supply, it’s best to check the most recent updates from Eli Lilly, pharmacies, the FDA, or other official health advisories.